First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase
December 05, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase
November 30, 2022 07:00 ET
|
First Wave BioPharma, Inc.
Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to...
First Wave BioPharma, Inc. Announces Closing of Private Placement
November 22, 2022 16:15 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma, Inc. Announces Private Placement
November 21, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 21, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
November 16, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation
October 31, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360
October 10, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 10, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering
October 06, 2022 21:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference
September 28, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
September 19, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...